We are live on ! Find out more
BSX icon

Boston Scientific

1,688 hedge funds and large institutions have $145B invested in Boston Scientific in 2025 Q2 according to their latest regulatory filings, with 154 funds opening new positions, 751 increasing their positions, 552 reducing their positions, and 91 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more first-time investments, than exits

New positions opened: 154 | Existing positions closed: 91

36% more repeat investments, than reductions

Existing positions increased: 751 | Existing positions reduced: 552

26% more call options, than puts

Call options by funds: $1.08B | Put options by funds: $859M

7% more capital invested

Capital invested by funds: $135B → $145B (+$10B)

3% more funds holding

Funds holding: 1,6431,688 (+45)

0.75% more ownership

Funds ownership: 90.79%91.53% (+0.75%)

18% less funds holding in top 10

Funds holding in top 10: 5142 (-9)

Holders
1,688
Holders Change
+45
Holders Change %
+2.74%
% of All Funds
22.22%
Holding in Top 10
42
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-17.65%
% of All Funds
0.55%
New
154
Increased
751
Reduced
552
Closed
91
Calls
$1.08B
Puts
$859M
Net Calls
+$225M
Net Calls Change
-$30.7M
Name Holding Trade Value Shares
Change
Change in
Stake
CPCPP
551
Canada Post Corporation Pension Plan
Canada
$4.97M +$4.68M +46,237 New
BIP
552
Bouvel Investment Partners
Pennsylvania
$4.94M +$80.9K +800 +2%
JWM
553
Jackson Wealth Management
Florida
$4.91M -$531K -5,248 -10%
FDP
554
Financiere des Professionnels
Quebec, Canada
$4.89M -$1.85M -18,247 -29%
VAS
555
Vestmark Advisory Solutions
Massachusetts
$4.89M -$3.35M -33,131 -42%
AHC
556
Adell Harriman & Carpenter
Texas
$4.88M +$2M +19,735 +77%
NRS
557
Neville Rodie & Shaw
New York
$4.88M +$2.25M +22,255 +96%
SNB
558
Security National Bank
Nebraska
$4.86M +$617K +6,102 +16%
HWM
559
HB Wealth Management
Georgia
$4.86M +$658K +6,502 +17%
AG
560
Ascent Group
Virginia
$4.85M -$485K -4,794 -10%
CWP
561
Cyndeo Wealth Partners
Florida
$4.82M +$160K +1,586 +4%
ACM
562
Aubrey Capital Management
United Kingdom
$4.73M
UCFA
563
United Capital Financial Advisors
Texas
$4.67M -$41.9K -414 -0.9%
PIM
564
Penobscot Investment Management
Massachusetts
$4.58M +$1.03M +10,177 +31%
AAM
565
Advisors Asset Management
Colorado
$4.51M +$627K +6,199 +17%
ETC
566
Exchange Traded Concepts
Oklahoma
$4.5M +$3.12M +30,824 +279%
SC
567
Saturna Capital
Washington
$4.49M +$1.55M +15,286 +58%
AI
568
Atria Investments
North Carolina
$4.48M -$289K -2,859 -6%
TCM
569
Twin Capital Management
Pennsylvania
$4.46M +$87.5K +865 +2%
CAM
570
Costello Asset Management
Pennsylvania
$4.41M -$2.05M -20,288 -33%
FAM
571
Fulcrum Asset Management
United Kingdom
$4.38M +$4.13M +40,804 New
SFA
572
Sequoia Financial Advisors
Ohio
$4.38M +$232K +2,293 +6%
PAG
573
Private Advisor Group
New Jersey
$4.37M +$247K +2,440 +6%
GVAG
574
Great Valley Advisor Group
Delaware
$4.37M +$185K +1,830 +5%
SW
575
Simplicity Wealth
New Jersey
$4.32M +$2M +19,800 +97%

BSX Hedge Fund Activity: Q2 2025 in Review

1,688 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Boston Scientific (BSX) for Q2 2025, worth a combined $145B — up 7.4% from $135B a quarter earlier.

Buyers outnumbered sellers: 154 funds opened new BSX positions and 91 closed out — a net gain of 63 holders — while 751 added to existing stakes and 552 trimmed.

The largest buyer was Edgewood Management, opening a new position worth an estimated $703M. The largest seller was Fidelity Investments, cutting an estimated $2.05B.

  • 1,688 institutional investors held Boston Scientific (BSX) as of Q2 2025, up from 1,643 in Q1 2025.
  • Funds reported $145B of Boston Scientific stock for Q2 2025, up 7.4% quarter-over-quarter.
  • 154 funds opened new Boston Scientific positions in Q2 2025 and 91 closed out, a net change of +63 holders.
  • The largest Boston Scientific buyer in Q2 2025 was Edgewood Management, an estimated $703M added.
  • The largest Boston Scientific seller in Q2 2025 was Fidelity Investments, an estimated $2.05B sold.

Based on aggregated 13F filings for Q2 2025.